Current Obesity Reports, Год журнала: 2024, Номер 13(4), С. 818 - 830
Опубликована: Авг. 7, 2024
Язык: Английский
Metabolism, Год журнала: 2024, Номер 161, С. 156028 - 156028
Опубликована: Сен. 11, 2024
Язык: Английский
Процитировано
25
Journal of Hepatology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
21
Med, Год журнала: 2024, Номер 5(7), С. 797 - 815.e2
Опубликована: Апрель 26, 2024
Язык: Английский
Процитировано
20
Annals of Hepatology, Год журнала: 2024, Номер 29(5), С. 101512 - 101512
Опубликована: Май 6, 2024
Fatty liver disease is a multisystem disease. Metabolic dysfunction-associated fatty (MAFLD) more accurate indicator of chronic kidney (CKD) than nonalcoholic (NAFLD). However, the relationship between recently defined metabolic steatotic (MASLD) and CKD currently unclear. The objective this cross-sectional study was to investigate prevalence albuminuria among individuals diagnosed with either MAFLD or MASLD.
Язык: Английский
Процитировано
20
Gut, Год журнала: 2024, Номер 73(11), С. 1883 - 1892
Опубликована: Авг. 1, 2024
Background Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim To explore the effects of statins on long-term risk all-cause mortality, liver-related clinical events (LREs) and stiffness progression MASLD. Methods This cohort study collected data MASLD undergoing at least two vibration-controlled transient elastography examinations 16 tertiary referral centres. Cox regression analysis was performed to examine association between statin usage mortality LREs stratified by compensated advanced chronic (cACLD): baseline measurement (LSM) ≥10 kPa. Liver defined as an LSM increase ≥20% for cACLD from <10 kPa or non-cACLD. reduction decrease cACLD. Results We followed up 7988 5.9 (IQR 4.6–8.2) a median 4.6 years. At baseline, 40.5% used statins, present 17%. Statin significantly associated lower (adjusted HR=0.233; 95% CI 0.127 0.426) HR=0.380; 0.268 0.539). also rates (HR=0.542; 0.389 0.755) non-cACLD HR=0.450; 0.342 0.592), but not HR=0.914; 0.778 1.074). Conclusions relatively
Язык: Английский
Процитировано
19
Journal of Advanced Research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Flavonoids are naturally occurring dietary phytochemicals with significant antioxidant effects aside from several health benefits. People often consume them in combination other food components. Compiling data establishes a link between bioactive flavonoids and prevention of diseases animal models, including cardiovascular diseases, diabetes, gut dysbiosis, metabolic dysfunction-associated steatotic liver disease (MASLD). However, numerous clinical studies have demonstrated the ineffectiveness contradicting rodent thereby challenging validity using as supplements. This review provides perspective to emphasize effective roles well summarize their specific mechanisms animals briefly. First, this offers an in-depth elucidation processes within human, encompassing small, large intestine, liver. Furthermore, comprehensive overview various functions gastrointestinal tract, hindering breakdown assimilation macronutrients, such polysaccharides lipids, regulating hormone secretion inhibition mineral iron absorption. In unabsorbed major portion interact flora leading biotransformation. Once absorbed circulated bloodstream, or metabolites exert beneficial systemic effects. Lastly, we examine protective disorders, endothelial dysfunction, MASLD, disease, obesity, hyperlipidemia, insulin resistance. conclusion, outlines safety future prospects field health, especially syndrome (MetS).
Язык: Английский
Процитировано
3
Cardiovascular Diabetology, Год журнала: 2025, Номер 24(1)
Опубликована: Янв. 13, 2025
Triglyceride-glucose (TyG) related indices, which serve as simple markers for insulin resistance, have been closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular (CVD), and mortality. However, the prognostic utility of TyG-related indices in predicting risk CVD mortality among patients with MASLD remains unclear. Data 97,331 patients, a median age 58.0 years free at baseline, were obtained from UK Biobank. The TyG index, along its combination adiposity parameters (i.e. body mass index [BMI], waist circumference [WC], waist-to-height ratio [WHtR]), calculated. Cox proportional hazards models restricted cubic spline (RCS) performed evaluate associations between overall CVD, coronary heart (CHD), stroke, all-cause mortality, Additionally, Harrell's C-index, net reclassification (NRI), integrated discrimination improvement (IDI) used assess predictive performance these indices. Over follow-up 13.56 years, we identified 13,256 cases 10,980 CHD, 2,926 8,809 1,796 Compared lowest quartile participants high had significantly increased incident Specifically, hazard ratios occurring fourth versus first quartiles 1.19 (95% confidence interval: 1.13-1.25) TyG, 1.35 (1.28-1.42) TyG-BMI, 1.33 (1.26-1.40) TyG-WC, 1.39 (1.32-1.46) TyG-WHtR. RCS analyses indicated nonlinear association outcomes (all P values nonlinearity < 0.05), whereas there exhibited linear trends TyG-WHtR > 0.05, except TyG-WC stroke). Furthermore, demonstrated higher NRI, IDI patients. especially TyG-WHtR, significant individuals MASLD. may effective surrogate predictors
Язык: Английский
Процитировано
3
Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)
Опубликована: Фев. 4, 2025
Abstract As a highly complex organ with digestive, endocrine, and immune-regulatory functions, the liver is pivotal in maintaining physiological homeostasis through its roles metabolism, detoxification, immune response. Various factors including viruses, alcohol, metabolites, toxins, other pathogenic agents can compromise function, leading to acute or chronic injury that may progress end-stage diseases. While sharing common features, diseases exhibit distinct pathophysiological, clinical, therapeutic profiles. Currently, contribute approximately 2 million deaths globally each year, imposing significant economic social burdens worldwide. However, there no cure for many kinds of diseases, partly due lack thorough understanding development these Therefore, this review provides comprehensive examination epidemiology characteristics covering spectrum from conditions manifestations. We also highlight multifaceted mechanisms underlying initiation progression spanning molecular cellular levels networks. Additionally, offers updates on innovative diagnostic techniques, current treatments, potential targets presently under clinical evaluation. Recent advances pathogenesis hold critical implications translational value novel strategies.
Язык: Английский
Процитировано
3
Journal of Gastroenterology and Hepatology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 16, 2025
ABSTRACT Background Resmetirom, the first FDA‐approved drug for nonalcoholic steatohepatitis (NASH) with fibrosis in obese patients, when combined lifestyle modifications, improves NASH resolution and reduces by at least one stage. Low thyroid hormone (T 3 ) levels are linked to a higher risk of developing metabolic dysfunction‐associated steatotic liver disease (MASLD). Epidemiological studies have confirmed positive correlation between hypothyroidism MASLD. Unraveling molecular mechanisms T signaling pathways MASLD will enhance prospects identifying effective specific targets. Therefore, this review discusses significant role hormones homeostasis fat metabolism describes possible thyromimetics treatment Methods A comprehensive search PubMed EMBASE was conducted using keywords “thyromimetics diseases,” “thyroid “hypothyroidism “T , 4 disease,” “resmetirom disease.” Relevant papers published before October 2024 were included. Results enhances mitochondrial respiration, biogenesis, β‐oxidation, mitophagy, reducing lipid accumulation. However, causes cardiotoxicity through receptor (THR)α agonistic activity. To address this, molecules high THRβ but lower THRα activity been developed. Besides resmetirom, other agonists like TG68, CS27109, MB07811, KB‐141 show promising results experimental studies. These upregulate target genes, activate genes fatty acid β‐oxidation mitochondria breakdown peroxisomes, downregulate involved de novo lipogenesis, reduce inflammation downregulating NF‐κB/JNK/STAT3 pathways, accelerate expressions marker tissue. Conclusion Future clinical should thoroughly investigate agonists, including KB‐141.
Язык: Английский
Процитировано
2
Lipids in Health and Disease, Год журнала: 2024, Номер 23(1)
Опубликована: Апрель 2, 2024
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic that affects over 30% world’s population. For decades, heterogeneity non-alcoholic fatty (NAFLD) has impeded our understanding mechanism and development effective medications. However, a recent change in nomenclature from NAFLD to MASLD emphasizes critical role systemic metabolic dysfunction pathophysiology this therefore promotes progress pharmaceutical treatment MASLD. In review, we focus on underlying abnormality hepatic lipid metabolism patients with MASLD, summarize latest therapeutic medications target disorders.
Язык: Английский
Процитировано
13